DOCSLIB.ORG

NEWSLETTER No.6

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
NEWSLETTER No.6 2015 WHO Pharmaceuticals NEWSLETTER No.6 Prepared in collaboration with the WHO Collaborating Centre for International Drug Monitoring, Uppsala Sweden The WHO Pharmaceuticals Newsletter provides you The aim of the Newsletter is to with the latest information on the safety of medicines disseminate information on the and legal actions taken by regulatory authorities across safety and efficacy of pharmaceutical products, based on the world. It also includes write-ups on ‘Signals’ from communications received from our Individual Case Safety Reports (ICSRs) available in the network of "drug information WHO Global ICSR database, VigiBase®. officers" and other sources such as specialised bulletins and journals, This newsletter includes three feature articles as well as partners in WHO. describing: the 38th meeting of the WHO International Working Group for Drug Statistics Methodology; Pre- The information is produced in the conference Workshop on WHO ATC/DDD Methodology form of résumés in English, full and Drug Utilization Research; and the 38th Annual texts of which may be obtained on Meeting of Representatives of the National request from: Pharmacovigilance Centres participating in the WHO Safety and Vigilance, Programme for International Drug Monitoring. EMP-HIS, World Health Organization, 1211 Geneva 27, Switzerland, E-mail address: [email protected] This Newsletter is also available on our Internet website: http://www.who.int/medicines Further information on adverse Contents reactions may be obtained from the WHO Collaborating Centre for International Drug Monitoring Box 1051 Regulatory matters 751 40 Uppsala Tel: +46-18-65.60.60 Safety of medicines Fax: +46-18-65.60.80 E-mail: [email protected] Signal Internet: http://www.who-umc.org Feature © World Health Organization 2015 All rights reserved. Publications of the World Health Organization can be obtained from WHO Press, World Health Organization, 20 Avenue Appia, 1211 Geneva 27, Switzerland (tel.: +41 22 791 3264; fax: +41 22 791 4857; e-mail: [email protected]). Requests for permission to reproduce or translate WHO publications – whether for sale or for non-commercial distribution – should be addressed to WHO Press, at the above address (fax: +41 22 791 4806; e-mail: [email protected]). The designations employed and the presentation of the material in this publication do not imply the expression of any opinion whatsoever on the part of the World Health Organization concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted lines on maps represent approximate border lines for which there may not yet be full agreement. The mention of specific companies or of certain manufacturers’ products does not imply that they are endorsed or recommended by the World Health Organization in preference to others of a similar nature that are not mentioned. Errors and omissions excepted, the names of proprietary products are distinguished by initial capital letters. All reasonable precautions have been taken by the World Health Organization to verify the information contained in this publication. However, the published material is being distributed without warranty of any kind, either expressed or implied. The responsibility for the interpretation and use of the material lies with the reader. In no event shall the World Health Organization be liable for damages arising from its use. Printed by the WHO Document Production Services, Geneva, Switzerland Table of Contents Regulatory Matters Aripiprazole ....................................................................................... 5 Asunaprevir and daclatasvir ................................................................. 5 Azithromycin ...................................................................................... 5 Ceftriaxone ........................................................................................ 6 Clopidogrel ........................................................................................ 6 Codeine ............................................................................................. 6 Dipeptidyl peptidase-4 (DPP-4) Inhibitors .............................................. 7 Dutasteride ........................................................................................ 7 Galantamine ...................................................................................... 7 Hepatitis C treatments (Viekira Pak® and Technivie®) ........................... 7 Iodine-containing contrast agents for medical imaging ............................ 8 Magnesium oxide ............................................................................... 8 Mirabegron ........................................................................................ 8 Roxithromycin .................................................................................... 9 Sodium glucose co-transporter 2 (SGLT2) inhibitors ............................... 9 Strontium ........................................................................................ 10 Testosterone .................................................................................... 10 Ustekinumab ................................................................................... 11 Vemurafenib .................................................................................... 11 Safety of medicines Crizotinib ......................................................................................... 12 Entacapone...................................................................................... 12 Infliximab ........................................................................................ 12 Newer rotavirus vaccines (Rotarix® and RotaTeq®) ............................. 13 Sodium glucose co-transporter 2 (SGLT2) inhibitors ............................. 13 Sodium polystyrene sulfonate ............................................................ 14 Tramadol ......................................................................................... 14 Vemurafenib .................................................................................... 14 WHO Pharmaceuticals Newsletter No. 6, 2015 3 Table of Contents Signal Atomoxetine and neutropenia in paediatric patients .............................. 16 Deferasirox and pancreatitis in paediatric patients ................................ 20 Desloratadine and aggressive reaction ................................................ 25 Feature The 38th meeting of the WHO International Working Group for Drug Statistics Methodology, Oslo, 22–23 October 2015 ............................... 32 Pre-conference Workshop on WHO ATC/DDD Methodology and Drug Utilization Research, New Delhi, India, 2-3 November 2015. .................. 33 The 38th Annual Meeting of Representatives of the National Pharmacovigilance Centres participating in the WHO Programme for International Drug Monitoring ............................................................ 34 WHO Pharmaceuticals Newsletter No. 6, 2015 4 Regulatory Matters Aripiprazole information involving Reference: aripiprazole to investigate Revision of Precautions, Risk of certain impulse potential harms. MHLW/PMDA, 20 October 2015 (www.pmda.go.jp/english/) control behaviours Reference: Summary Safety Review, Canada. Health Canada has Health Canada, 2 November updated the Canadian 2015 (www.hc-sc.gc.ca) prescribing information for Azithromycin aripiprazole (Abilify®) to include a warning statement of Risk of drug reaction risk of pathological gambling Asunaprevir and with eosinophilia and and uncontrollable sexual systemic symptoms behaviours (hypersexuality). daclatasvir (DRESS) Aripiprazole is an oral medication and is used to Risk of interstitial Singapore. The Health treat: pneumonia Sciences Authority (HSA) has manic-depressive illness informed health-care (bipolar I disorder) in adults Japan. The Ministry of Health, professionals of the risk of and adolescents of 13 years Labour and Welfare (MHLW) eosinophilia and systemic and older. This condition is and the Pharmaceuticals and symptoms (DRESS) associated characterised by periods of Medical Devices Agency with the use of azithromycin. elevated moods (mania) (PMDA) have announced the Azithromycin (Zithromax®) is and depression; revision of the package insert a macrolide antibiotic (azalide schizophrenia in adults and for asunaprevir (Sunvepra®) subclass) used to treat upper adolescents of 15 years and and daclatasvir (Daklinza®) to and lower respiratory tract older; include risk of interstitial infections and other infections depression in adults when pneumonia. sensitive to azithromycin. used in combination with Asunaprevir and daclatasvir other drugs. are co-administered for In April 2014, Health Canada updated package inserts (PI) Health Canada conducted a treatment of serogroup 1 of azithromycin-containing safety review following the (genotype 1) chronic hepatitis products to include information European Medicines Agency C or compensated cirrhosis on DRESS. This was based on (EMA)’s warning (product label type C. a report of DRESS suspected update) of the risk of The MHLW/PMDA stated that to be associated with pathological gambling and the cases of interstitial pneumonia azithromycin in Canada, and a inclusion of hypersexuality as have been reported in patients review of published literature. an adverse effect. treated with asunaprevir and To date, the HSA has not At the time of the review, daclatasvir in Japan.
Load more

Recommended publications
  • Download a Drug Interactions Card
    transplant.bc.ca/medications Please discuss with your healthcare professionals BEFORE starting or stopping any medications, herbal or non-prescription products. Contact your Transplant Clinic nurse or pharmacist to let them know if there are any changes to your medications. Transplant Clinic Phone: _____________________________________ BC PHN (CareCard #) __________________________________ (2017v3) Please call your transplant clinic before starting any new medications to avoid possible drug interactions, especially those with CAUTION (see below) next to its name: Cyclosporine (Neoral), Tacrolimus (Prograf/Sandoz tac, Advagraf), Sirolimus (Rapamune): Seizure: phenytoin, carbamazepine, phenobarbital, primidone Infection: erythromycin, clarithromycin – CAUTION ( OK- azithromycin) fluconazole, ketoconzazole, posaconazole voriconazole - CAUTION rifampin – CAUTION Cyclosporine (Neoral), Tacrolimus (Prograf/Sandoz tac, d Advagraf), Sirolimus (Rapamune) cont’d Depression: fluoxetine, fluvoxamine ( OK- paroxetine, citalopram, escitalopram, sertraline, venlafaxine, mirtazapine) Heart/Blood pressure: diltiazem, verapamil, amiodarone, digoxin Cholesterol: lovastatin, simvastatin, atorvastatin ( OK- rosuvastatin, pravastatin, fluvastatin) Pain: anti-inflammatories can affect kidney function: ibuprofen, naproxen, diclofenac, indomethacin, celecoxib ( OK- acetaminophen) Mycophenolate mofetil/sodium (MMF, Cellcept/Myfortic): Antacids: space taking antacid and MMF by 2 hours Cholestyramine: AVOID if possible Azathioprine (Imuran): Gout: allopurinol –
    [Show full text]
  • PACKAGE LEAFLET: INFORMATION for the PATIENT Desloratadine 5
    PACKAGE LEAFLET: INFORMATION FOR THE PATIENT Desloratadine 5 mg tablets Read all of this leaflet carefully before you start taking/using this medicine because it contains important information for you. Keep this leaflet. You may need to read it again. If you have any further questions, ask your doctor, pharmacist or nurse. This medicine has been prescribed for you only. Do not pass it on to others. It may harm them, even if their signs of illness are the same as yours. If you get any side effects, talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed in this leaflet. See section 4. What is in this leaflet 1. What Desloratadine 5 mg Tablets are and what they are used for 2. What you need to know before you take Desloratadine 5 mg Tablets 3. How to take Desloratadine 5 mg Tablets 4. Possible side effects 5. How to store Desloratadine 5 mg Tablets 6. Contents of the pack and other information 1. What Desloratadine 5 mg Tablets are and what they are used for What Desloratadine 5 mg Tablets is Desloratadine 5 mg Tablets contain desloratadine which is an antihistamine. How Desloratadine 5 mg Tablets works Desloratadine 5 mg Tablets is an antiallergy medicine that does not make you drowsy. It helps control your allergic reaction and its symptoms. When Desloratadine 5 mg Tablets should be used Desloratadine relieves symptoms associated with allergic rhinitis (inflammation of the nasal passages caused by an allergy, hay fever or allergy to dust mites) in adults and adolescents 12 years of age and older.
    [Show full text]
  • Alternative Forms of Oral Drug Delivery for Pediatric Patients Marcia L
    PEDIATRIC PHARMACOTHERAPY A Monthly Newsletter for Health Care Professionals from the University of Virginia Children’s Hospital Volume 19 Number 3 March 2013 Alternative Forms of Oral Drug Delivery for Pediatric Patients Marcia L. Buck, Pharm.D., FCCP, FPPAG he lack of an appropriate dosage form the concentration versus time curve (AUC) of T limits the use of many medications that 45% for lopinavir and 47% for ritonavir (p = may potentially benefit children. While this has 0.003 and 0.006, respectively). been a long-standing problem for pediatric healthcare providers, little attention has been Cutting tablets, another common practice, may paid to remedying it until recently. In 2005 the be acceptable for some drugs, however this Eunice Kennedy Shriver National Institute for practice can introduce considerable variability Child Health and Human Development, joined between doses. In drugs with a narrow by representatives from the Food and Drug therapeutic index, such as levothyroxine, this Administration (FDA), academic medicine, and variability may be enough to produce clinically the pharmaceutical industry, formed the United significant changes in clinical response.7 When States (US) Pediatric Formulations Initiative in cutting a tablet is necessary, family members an effort to stimulate research in pediatric should receive specific instructions on the formulation technology.1 Similar work by the process, including the proper use of a tablet European Medication Agency (EMA) led to the splitter. Family members involved in dose development of the European Pediatric preparation should also understand how to Formulation Initiative.2 In addition, the World dispose of unused drug and the need to avoid Health Organization launched a global initiative repeated exposure to drugs that have in 2007 entitled “Make Medicines Child Size” to carcinogenic or teratogenic properties.
    [Show full text]
  • Evaluation of the Efficacy of the Utilization of the Imipramine For
    vv Clinical Group Archives of Otolaryngology and Rhinology ISSN: 2455-1759 DOI CC By Diaa El Din El Hennawi, Mohamed Rifaat Ahmed*, Yasser T Madian, Research Article Mohammed T El-Tabbakh and Ibrahim Hassan Ibrahim Evaluation of the efficacy of the Department of Otorhinolaryngology, Faculty of utilization of the imipramine for medicine Suez Canal University, Ismailia – Egypt Dates: Received: 13 May, 2017; Accepted: 22 July, patients with allergic rhinitis 2017; Published: 26 July, 2017 *Corresponding author: Mohamed Rifaat Ahmed, MD, Assistant Professor, Otolaryngology, Fac- ulty of Medicine, Suez Canal University, Ismailia, Abstract Egypt, Tel: +201285043825; Fax: +20663415603; E-mail: Background: allergic rhinitis is an infl ammatory process of the upper respiratory tract with a continuous symptom that last for hour or more with symptom affect patient’s work and quality of life. Keywords: Allergic rhinitis; Imipramine; Desloratadine; Randomized controlled trial Methodology: a randomized controlled trial in which we enrolled 284 patients with allergic rhinitis for periods longer than 4 days/week and for more than 4 consecutive weeks divided into two groups. https://www.peertechz.com Group A (n=142) received Imipramine 75 mg/day for 90 days .Group B (n=142), the control group, received desloratadine 5 mg / day for 90 days. Results: The mean visual analogue score nasal symptoms intensity (sneezing, Nasal obstruction, watery rhinorrhea and itchy nose) showed a statistically signifi cantly improvement in group A (treated with Imipramine) compared with group B (treated with desloratadine) after the same treatment period. Conclusion: Imipramine could be used in treatment patients with allergic rhinitis as it is effective as an antihistaminic besides its main action in reliving psychosocial stresses.
    [Show full text]
  • Medications That May Interfere with Skin Testing
    MEDICATIONS THAT MAY INTERFERE WITH SKIN TESTING • Due to continued advances, not all medications may be listed at time of printing. • For your safety and accurate results, at each visit, please list all your current medications (including non-prescription and those prescribed elsewhere). • It is important to let us know if you are pregnant or could be pregnant. STOP THESE MEDICATIONS FIVE DAYS BEFORE SKIN TESTING: ORAL ANTIHISTAMINES: ANTIHISTAMINE NOSE SPRAYS: • Allegra (Fexofenadine) • Astelin, Astepro, Dymista (Azelastine) • Benadryl (Diphenhydramine) • Patanase (Olopatadine) • Claritin, Alavert (Loratadine) • Clarinex (Desloratadine) ANTIHISTAMINE EYE DROPS: • Xyzal (Levocetirizine) • Alaway, Claritin, Zaditor, Zyrtec (Ketotifen) • Zyrtec (Cetirizine) • Bepreve (Bepotastine) • Cyproheptadine • Elestat (Epinastine) · All over-the-counter medications for allergy, cough, cold, sleep, • Emadine (Emedastine) or nausea that include: • Lastacaft (Alcaftadine) oAcrivastine (ex. Semprex) • Livostin (Levocabastine) oAzatadine (ex. Optimine, Trinalin) • Naphcon-A, Opcon-A, Visine-A oBrompheniramine (ex. Dimetapp) (Pheniramine) oCarbinoxamine (ex. Palgic, Arbinoxa) • Optivar (Azelastine) oChlorpheniramine (ex. Actifed, Aller-chlor, Chlor- • Pataday, Patanol (Olopatadine) Trimeton, Tylenol Allergy) oDimenhydrinate (ex. Dramamine) HEARTBURN MEDICATIONS (H2 BLOCKERS): oDiphenhydramine (ex. Unisom, Sominex, • Axid (Nizatidine) Triaminic, many with “PM” in the title) • Pepcid, Tums Dual Action (Famotidine) oDoxylamine (ex. Nyquil, Unisom) • Tagament
    [Show full text]
  • Orodispersible Tablets Im Mund Dispergierbare Tabletten Comprimés Orodispersibles
    (19) TZZ Z_T (11) EP 2 572 705 B1 (12) EUROPEAN PATENT SPECIFICATION (45) Date of publication and mention (51) Int Cl.: of the grant of the patent: A61K 9/00 (2006.01) A61K 9/20 (2006.01) 13.09.2017 Bulletin 2017/37 A61K 31/551 (2006.01) A61K 31/422 (2006.01) A61K 31/4178 (2006.01) (21) Application number: 12198042.9 (22) Date of filing: 30.09.2008 (54) Orodispersible tablets Im Mund dispergierbare Tabletten Comprimés orodispersibles (84) Designated Contracting States: • Díez Martín, Ignacio AT BE BG CH CY CZ DE DK EE ES FI FR GB GR E-08980 Sant Feliu de Llobregat - Barcelona (ES) HR HU IE IS IT LI LT LU LV MC MT NL NO PL PT • Pablo Alba, Pablo RO SE SI SK TR E-08940 Cornella de Llobregat - Barcelona (ES) (30) Priority: 01.10.2007 EP 07380265 (74) Representative: ABG Patentes, S.L. 03.10.2007 US 977166 P Avenida de Burgos, 16D Edificio Euromor (43) Date of publication of application: 28036 Madrid (ES) 27.03.2013 Bulletin 2013/13 (56) References cited: (62) Document number(s) of the earlier application(s) in EP-A- 1 488 811 EP-A- 1 681 048 accordance with Art. 76 EPC: WO-A1-03/045844 WO-A2-2004/105680 08804908.5 / 2 205 213 DE-A1-102005 009 241 (73) Proprietor: Laboratorios Lesvi, S.L. • "Orally disintegrating pharmaceutical 08970 Sant Joan Despí - Barcelona (ES) composition", IP.COM JOURNAL, IP.COM INC., WEST HENRIETTA, NY, US, 11 September 2006 (72) Inventors: (2006-09-11), XP013115762, ISSN: 1533-0001 • Úbeda Pérez, Carmen E-08348 Cabrils - Barcelona (ES) Note: Within nine months of the publication of the mention of the grant of the European patent in the European Patent Bulletin, any person may give notice to the European Patent Office of opposition to that patent, in accordance with the Implementing Regulations.
    [Show full text]
  • Thermodynamic Investigation of Promethazine, Loratadine, Cetirizine and Buclizine As Antihistamine Drugs; Monte Carlo and Semi-Empirical Studies
    ISSN-E 1995-9516 Universidad Nacional de Ingeniería COPYRIGHT © (UNI). TODOS LOS DERECHOS RESERVADOS http://revistas.uni.edu.ni/index.php/Nexo https://doi.org/10.5377/nexo.v33i01.10050 Vol. 33, No. 01, pp. 94-108/Junio 2020 THERMODYNAMIC INVESTIGATION OF PROMETHAZINE, LORATADINE, CETIRIZINE AND BUCLIZINE AS ANTIHISTAMINE DRUGS; MONTE CARLO AND SEMI-EMPIRICAL STUDIES INVESTIGACIÓN TERMODINÁMICA DE PROMETAZINA, LORATADINA, CETIRIZINA Y BUCLIZINA COMO MEDICAMENTOS ANTIHISTAMÍNICOS; MONTE CARLO Y ESTUDIOS SEMI-EMPÍRICOS Mina Zakeri1, Majid Monajjemi2*, Ali Ebrahimi3 1Department of Chemistry, Science and Research Branch, Islamic Azad University, Tehran, Iran 2Department of Chemical Engineering, Central Tehran branch, Islamic Azad University Tehran, Iran 3Department of chemistry, Computational Quantum Chemistry Laboratory, University of Sistan and Baluchestan, Iran *[email protected] (recibido/received: 14-diciembre-2019; aceptado/accepted: 21-febrero-2020) ABSTRACT In this article, we discussed about four antihistamine drug called promethazine, loratadine, cetirizine and buclizine. Promethazine in this list is the only one in first generation antihistamine classification with CNS sedation effect and the other three belongs to second generation antihistamine group which are non- sedation and used to treat in many different anti-allergenic fields. In the following we optimized potential, kinetic and total energy of these molecules at body temperature (310 k˚) and environment temperature (298 k ˚) using Mont Carlo method in Amber force field in 500 ns. The quantum mechanics calculations and molecular structure of these molecules investigated using B3LYP level of theory with 6-31 G (d) as a basis set. Theoretical computations were performed to study thermodynamic parameters and frequency analysis. Electronic, thermal, zero point and gibs free energy and enthalpy were estimated in frequency analysis.
    [Show full text]
  • Simplete – High-Risk Medications for Aging Adults
    Simplete – High-Risk Medications for Aging Adults Anticholinergics– Non-COX- Tricyclic Nonbenzodiazepine Sulfonylureas, Skeletal Muscle Drug Class First-Generation Anti-infective Cardiovascular Estrogen selective Antidepressants Hypnotics Long-Duration Relaxants Antihistamines NSAIDs High-Risk • Hydroxyzine Nitrofurantoin (for Digoxin • Amitriptyline • Lunesta Estrogen • Glyburide • Indomethacin • Carisoprodol Medications • Promethazine chronic use or in > 0.125 mg/day • Clomipramine (eszopiclone) • Glimepiride • Ketorolac • Chlorzoxazone to Avoid • Diphenhydramine patients with • Doxepin • Zaleplon • Cyclobenzaprine CrCl < 30) (> 6 mg/day) • Zolpidem • Metaxalone • Imipramine • Methocarbamol • Trimipramine • Orphenadrine • Nortriptyline • Desipramine Possible Nausea/Vomiting: • Cephalexin Lower dose of Depression: • Belsomra • Alendronate • Metformin • Ibuprofen Spasticity: Alternatives • Ondansetron • Doxycycline digoxin and • Venlafaxine • Melatonin • Calcium • Glipizide • Meloxicam • Baclofen • Prochlorperazine monitor level. • Rozerem • Naproxen • Amoxicillin/ • Bupropion • Vitamin D Muscle Spasm: Anxiety: • Silenor • Tizanidine Clavulanate • Sertraline Vaginal • Buspirone • Trimethoprim/ • Escitalopram Symptoms: • Escitalopram Sulfamethoxazole • Estradiol Neuropathic cream • Sertraline pain: Pruritus: • Premarin • Gabapentin • OTC cream • Pregabalin non-sedating Hot Flashes: • Duloxetine antihistamines • Femring • Desloratadine • Citalopram • Levocetirizine • Desvenlafaxine • Venlafaxine Reasons for the Recommendations Anticholinergics–First-Generation
    [Show full text]
  • Use of Phenotypically Poor Metabolizer Individual Donor
    DMD Fast Forward. Published on December 15, 2019 as DOI: 10.1124/dmd.119.089482 This article has not been copyedited and formatted. The final version may differ from this version. DMD #89486 Use of Phenotypically Poor Metaboliser Individual Donor Human Liver Microsomes to Identify Selective Substrates of UGT2B10 Nicolo Milani, Nahong Qiu, Birgit Molitor, Justine Badée, Gabriele Cruciani and Stephen Fowler Pharmaceutical Sciences, Roche Pharma Research and Early Development, Roche Innovation Centre Downloaded from Basel, Grenzacherstrasse 124, 4070, Basel, Switzerland (NM, NQ, BM, SF); Department of Chemistry, Biology and Biotechnology, University of Perugia, 06123 Perugia, Italy (NM, GC), Department of Pharmaceutics, Center for Pharmacometrics and Systems Pharmacology, University dmd.aspetjournals.org of Florida at Lake Nona, Orlando, Florida, USA (JB)* *Current Address: Modelling and Simulation, PK Sciences, Novartis Institutes for BioMedical Research, CH-4002, Basel, Switzerland. at ASPET Journals on September 23, 2021 1 DMD Fast Forward. Published on December 15, 2019 as DOI: 10.1124/dmd.119.089482 This article has not been copyedited and formatted. The final version may differ from this version. DMD #89486 Running title: Rapid detection of selective UGT2B10 substrates Corresponding author: Stephen Fowler, Pharmaceutical Sciences, Roche Pharma Research and Early Development, Roche Innovation Centre Basel, Grenzacherstrasse 124, 4070, Basel, Switzerland. Phone: +41 61 688 5105. Email:[email protected] Downloaded from Abbreviations: HLM: human liver microsomes, Km: Michaelis-Menten constant, MgCl2: magnesium chloride, LC: dmd.aspetjournals.org liquid chromatography, MS/MS: tandem mass spectrometry, UDPGA: uridine 5’- diphosphoglucuronic acid, UGT: Uridine 5’-diphospho (UDP)-glucuronosyltransferases, UHPLC: ultra-high performance liquid chromatography, NADPH: Nicotinamide adenine dinucleotide at ASPET Journals on September 23, 2021 phosphate, MIFs: Molecular Interaction Fields, Clint: intrinsic clearance, S.D.: standard deviation.
    [Show full text]
  • Medications to Avoid Before Skin Testing
    PLEASE STOP ANTIHISTAMINES 5 DAYS PRIOR TO NEW PATIENT APPOINTMENTS OR ALLERGY SKIN TESTING *Do not stop asthma medications or any other medications that do not contain antihistamine! **If you have major hives or swelling, do not stop your antihistamines. ***Please call us if you have questions about any of your medications interfering with skin testing. ****Do not use oil, cream or lotion on the back or arms for 24 hours prior to skin testing. COMMON MEDICATIONS CONTAINING ANTIHISTAMINES • Actifed (chlorpheniramine) • Elavil (amitriptyline) • Advil PM, Advil Allergy • Excedrin PM • Alavert/Claritin (loratadine) • Fexofenadine (Allegra) • Allegra (fexofenadine) • Hydroxyzine (Atarax, Vistaril) • Alka Seltzer P.M. • Imipramine (Tofranil) • Amitriptyline (Elavil) • Levocetirizine (Xyzal) • Antivert (Meclizine) • Loratadine (Claritin) • Astelin Nasal Spray (azelastine) • Meclizine (Antivert, Bonine) • Astepro Nasal Spray (azelastine) • Norpramine (desipramine) • Atarax (hydroxyzine) • Nortriptyline (Pamelor) • Azelastine nose spray (Astepro, Astelin) • Nyquil • Benadryl (diphenhydramine) • Nytol • Bonine (meclizine) • Olopatadine (Patanase nasal spray) • Cetirizine (Zyrtec) • Pamelor (nortriptyline) • Chlorpheniramine (Chlor-Trimeton, Actifed, • Patanase Nasal Spray (olopatadine) Tussionex) • PBZ (pyribenzamine) • Chlor-Trimeton (chlorpheniramine) • Pediacare • Clarinex (desloratadine) • Periactin (Cyproheptadine) • Claritin (loratadine) • Phenergan (promethazine) • Clemastine (Tavist) • Promethazine (Phenergan) • Cogentin (for Parkinson's
    [Show full text]
  • Validation of Cotinine As a Selective Probe Substrate, Inhibition by UGT Enzyme-Se
    Supplemental material to this article can be found at: http://dmd.aspetjournals.org/content/suppl/2015/12/15/dmd.115.068213.DC1 1521-009X/44/3/378–388$25.00 http://dx.doi.org/10.1124/dmd.115.068213 DRUG METABOLISM AND DISPOSITION Drug Metab Dispos 44:378–388, March 2016 Copyright ª 2016 by The American Society for Pharmacology and Experimental Therapeutics Human UDP-Glucuronosyltransferase (UGT) 2B10: Validation of Cotinine as a Selective Probe Substrate, Inhibition by UGT Enzyme-Selective Inhibitors and Antidepressant and Antipsychotic Drugs, and Structural Determinants of Enzyme Inhibition s Attarat Pattanawongsa, Pramod C. Nair, Andrew Rowland, and John O. Miners Department of Clinical Pharmacology (A.P., P.C.N., A.R., J.O.M.) and Flinders Centre for Innovation in Cancer (A.R., P.C.N., J.O.M.), Flinders University School of Medicine, Adelaide, Australia Received November 2, 2015; accepted December 14, 2015 ABSTRACT Downloaded from Although there is evidence for an important role of UGT2B10 in the antidepressant and antipsychotic drugs screened for effects on N-glucuronidation of drugs and other xenobiotics, the inhibitor UGT2B10 inhibited enzyme activity with IC50 values <100 mM. The selectivity of this enzyme is poorly understood. This study sought most potent inhibition was observed with the tricyclic antidepres- primarily to characterize the inhibition selectivity of UGT2B10 by sants amitriptyline and doxepin and the tetracyclic antidepressant UDP-glucuronosyltransferase (UGT) enzyme-selective inhibitors mianserin, and the structurally related compounds desloratadine dmd.aspetjournals.org used for reaction phenotyping, and 34 antidepressant and antipsy- and loratadine. Molecular modeling using a ligand-based approach chotic drugs that contain an amine functional group.
    [Show full text]
  • Antihistamines
    Leaders In Allergy & Asthma Care For Over 40 Years Antihistamines Actions: Antihistamines are medications which block the effects of histamine, which is released by allergy cells during allergic reactions. Types: There are many different brands of antihistamines. They are commonly used as capsules, tablets (swallowed or dissolvable), and liquids, all of which are taken by mouth. Most antihistamines are currently available OTC (over‐the‐counter); However there are a few that are still available only by prescription. The older antihistamines (1st generation) are typically more sedating and shorter acting. The newer antihistamines (2nd generation) are less sedating and longer acting. Examples of Antihistamines: 1st Generation: Atarax (hydroxyzine), Benadryl (diphenhydramine), Chlor‐Trimeton (chlorpheniramine), Doxepin, Tavist (clemastine), and Periactin (cyproheptadine). 2nd Generation: Allegra (fexofenadine), Claritin (loratadine), Clarinex (desloratadine), Zyrtec (cetirizine), and Xyzal (levocetirizine). Side Effects: Sedation and dryness are the most common side effects of antihistamines. These effects can occur with either 1st or 2nd generation antihistamines however, it is far more of an issue with the 1st generation antihistamines. Alcohol, tranquilizers, and other sedating medications may increase the sedative effects of antihistamines. If an antihistamine is combined with a decongestant, side effects may include nervousness, insomnia, irritability, palpitations, rapid heart beat. Consult your prescribing doctor if these side effects occur. Special Instructions: ● Notify your doctor if you: ○ Are pregnant or breast‐feeding ○ Have glaucoma ○ Have prostate problems ○ Have liver disease ○ Have a heart condition or high blood pressure ● Chronic hives: Your provider will frequently prescribe antihistamines at higher doses than is recommended on package labeling. ● Notify your provider of all other medications you are taking (prescription and OTC), since drug interactions or over‐dosages may occur.
    [Show full text]